Kromek have secured a new long-term order for use of their CZT-based detector module in a new medical diagnostics product.
The radiation detection technology company, focusing on the medical, security and nuclear markets, has announced that it has been awarded a new five-year contract.
The contract is with a customer in the bone mineral densitometry (BMD) sector for the incorporation of Kromek’s cadmium zinc telluride (CZT)-based detector modules in a new product.
Delivery on the contract, which is worth a minimum value of $5.38 million, is expected to begin in the current financial year.
Dr Arnab Basu, CEO of Kromek, said: “We are delighted to have secured a further contract with an existing BMD customer as they launch a new medical diagnostics product.
“It further validates our belief that, as customers move away from legacy diagnostic systems, CZT based detectors will become a core technology and we anticipate to be one of the major suppliers to this segment.
“The agreement also demonstrates the strong relationships we build with our customers and the Company’s commitment to securing further contracts in the medical imaging sector.”
Kromek Group plc is a UK technology group that has its global headquarters in County Durham. It is a leading developer of high performance radiation detection products based on cadmium zinc telluride and other advanced technologies.
Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma photon imaging ad well as radiation detection products for the medical, security screening and nuclear markets.
The Group’s products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.